Skip to main content

TNF inhibitor

DMARDs, MTX & TNFi can lower CV risk in RA pts. #RWCS24 https://t.co/Un457RYL8R
Dr. John Cush @RheumNow( View Tweet )
Feb 16, 2024
Combo IL-23 and TNFi synergistic benefit in UC in the proof-of-concept VEGA trial. More data to come! #RWCS24 @RWCSmtg @RheumNow https://t.co/FgLTR2PBYJ
Dr. Rachel Tate @uptoTate( View Tweet )
Feb 16, 2024
Dr. J. Giles reviews adipose tissue as a source of inflammatory cytokines like TNF, IL-6, IL-1, IL17, etc. #RWCS24 @RWCSmtg @RheumNow https://t.co/AYD9PpwNE6
Dr. Rachel Tate @uptoTate( View Tweet )
Feb 16, 2024
#RWCS24 @JointMD @RWCSmtg review the TNFi differences molecularly. @RheumNow https://t.co/6JAnNwwV0n
Dr. Rachel Tate @uptoTate( View Tweet )
Feb 16, 2024

Curbside Consults (2.16.2024)

Feb 16, 2024

Dr. Jack Cush answers audience clinical case questions sent by email or "ask Cush anything". Cases and questions from:



  • Dr. William Hong - RA management in the setting of active TB or latent TB (LTBI)

  • Dr. Vrishali Dalvi - relapsing polychondritis monitoring

  • Dr
Read Article

Co-management of Psoriatic Disease

It is a common clinical scenario to see someone with both severe psoriatic arthritis and skin psoriasis. In an ideal world this would involve a combined clinic with our local friendly dermatologist. For many of us, however, this is not practical for many reasons. The excellent Saturday morning

Read Article

VITAL Info on Autoimmune Disease (2.9.2024)

Feb 09, 2024

Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".




  1. Many #RA pts remain on Steroids despite b/tsDMARD use! Study 228 #RA pts,

Read Article

Pre-Treatment Testing with Biologics Falls Short

Feb 01, 2024

US commercial insurance claim analysis of laboratory screening and monitoring practices in chronic inflammatory skin disease (CISD) patients shows that < 60% received the recommended pretreatment testing when starting systemic immunomodulatory treatment.

Read Article
AS v nr-AxSpA for TNFi - no diff in response @JointMD @RheumNow #RNL2024 ADA: ASAS20 AS 58%, nr-AxSpA 52%, ASAS40 AS 39%, nr 36% (ATLAS, ABILITY-1) ETN: ASAS 20 59%/52%, ASAS50/40 44%/33% in p3 AS study v EMBARK CZP: RAPID-AxSpA - no diff bw AS & nr-AxSpA response in same trial https://t.co/Rau2CDYbY4
Eric Dein @ericdeinmd( View Tweet )
Jan 28, 2024
Rheumatology drugs in pregnancy. Just missing leflunomide in that big no no section @DrCassySims @RheumNow #RNL2024 https://t.co/ZPtTGRqPki
Richard Conway @RichardPAConway( View Tweet )
Jan 28, 2024
@reumacia @RheumNow You are absolutely right. The point was not generally used for psoriasis ( not PsA). I was surprised my self 🤕. Here is the slide again by Dr. Armstrong , great talk by the way. Let me know if you want the handout. https://t.co/C11Gkn2jho
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
Dr. Winthrop avoid JAKi and TNFi in pts with chronic lung infections like MAI. #RNL2024 @rheumnow https://t.co/TfMa7hktL9
TheDaoIndex @KDAO2011( View Tweet )
Jan 27, 2024
#RNL2024 @RheumNow @_AprilArmstrong Choosing a biologic in Psoriasis TNF - great in PsA, pregnancy. Avoid in demyelinating, hep B IL-17 - robust skin, PsA (axial too). Avoid in IBD IL-23 - robust skin, PsA evidence, fewer injections https://t.co/9Xt7Nx1tKq
Eric Dein @ericdeinmd( View Tweet )
Jan 27, 2024

Anti-Drug Antibodies and Biologic Drug Responses

Jan 25, 2024

A prospective cohort study suggests the presence of antidrug antibodies may be associated with bDMARDs nonresponse in rheumatoid arthritis (RA). Should we be monitoring ADAbs (especially in nonresponders)?

Read Article
Data from the American Rheumatology Network (2014–2021) shows that among 15182 new TNFi initiations, only 45% had a dz activity measure (CDAI/RAPID3); and of these, only 47% had a TJC, SJC or pain score. Can you treat HTN without measuring BP? https://t.co/SsnF7Taky1 https://t.co/LN72IAWs8n
Dr. John Cush @RheumNow( View Tweet )
Jan 18, 2024
Retrospective study of 170 #RA on TNFi (Inflx 53%, ADA 28%, CZP 19%). RF, CCP, Drug levels, anti-Drug Abs done.@6 mos HI baseline RF linked to lower drug levels for IFX & ADA; but not CZP. IFX/ADA Hi-RF pts had more dropouts vs CZP (80%/75%/33%, p=0.002) https://t.co/AIgJNkzcWu https://t.co/pQmfmLoFwe
Dr. John Cush @RheumNow( View Tweet )
Jan 16, 2024

Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs

Dec 26, 2023

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid

Read Article
Gender Gap Confirmed for TNF Inhibitor Response in Axial SpA Men with axial spondyloarthritis (axSpA) were more likely than women to obtain substantial relief with tumor necrosis factor (TNF) inhibitors, a multinational study indicated. https://t.co/ye5iReGLMG https://t.co/goKe0TuYqz
Dr. John Cush @RheumNow( View Tweet )
Dec 19, 2023

ICYMI: Effective Treatments for Rheumatoid Arthritis ILD

The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.

Read Article

RheumNow Podcast – Bill of Rights (12.15.2023)

Dec 15, 2023

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Two major reports on fatigue and fibromyalgia misfired, and "ankylosing spondylitis" is sent to the Rheumatology dead word cemetery. 

Read Article

Gender Gap Confirmed for TNF Inhibitor Response in Axial SpA

MedPage Today
Dec 14, 2023

Men with axial spondyloarthritis (axSpA) were more likely than women to obtain substantial relief with tumor necrosis factor (TNF) inhibitors, a multinational study indicated.

Read Article

ICYMI: Bimekizumab is Coming…in Third Place

Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab abstracts will be featured at this year’s meeting and it recently received authorization in Europe and

Read Article
ICYMI: Cancer and TNF inhibitors Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. https://t.co/rNSTcT5O6L https://t.co/f5lvMTH7ik
Dr. John Cush @RheumNow( View Tweet )
Dec 13, 2023

ICYMI: ACR Plenaries: Changing the Practice of Rheumatology

Dec 13, 2023

Over the years of navigating the annual meeting, I found the sessions with the most impact to my practice were the Plenary Sessions. During these sessions, the latest research is presented, new ideas are floated, and old myths debunked. Here are the top ACR2023 Plenary abstracts I found

Read Article